{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Participants with ≥2*10^6 CD34+ cells/kg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Participants with <2*10^6 CD34+ cells/kg"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"The number of patients with a circulating CD34+ count \\>= 5 and \\< 20 cells/ml after 5 days of mobilization with G-CSF alone who achieved cumulative apheresis yields of ≥2\\*10\\^6 CD34+ cells/kg within 3 days of apheresis after receiving G-CSF plus plerixafor. Outcome was based on laboratory results from a central lab.","groups":[{"description":"Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"All patients who received plerixafor.","reportingStatus":"POSTED","timeFrame":"approximately days 6-9","title":"Number of Patients Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor 240 µg/kg and G-CSF for up to 3 Consecutive Days","type":"PRIMARY","unitOfMeasure":"participants"}